ClinicalTrials.gg
CompletedNCT05263583Updated Nov 4, 2026

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

A Phase 2 interventional study of Sepantronium Bromide in High-grade B-cell Lymphoma, Burkitt Lymphoma and Lymphoma, B-Cell, sponsored by Cothera Bioscience, Inc. Completed at 11 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Cothera Bioscience, Inc · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 9 months ago, and no results have been posted to the registry.
Updated Nov 4, 2026Now CompletedStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 102 studies in Burkitt Lymphoma with a site in China — 58 open to participants now, 62 under way, 4 of them phase 3. Burkitt Lymphoma · China.

Enrollment
79th of 100
14 · median 24
Started
2022
with 11 others
Phase 2
15 of 102
9 open now
Registered
36th of 102
by date

Among the 102 studies in Burkitt Lymphoma with a site in China, this one is the 79th largest by enrollment of the 100 interventional ones that give a count, is one of 12 that started in 2022, is one of 15 in phase 2, and was the 36th registered.

Burkitt Lymphoma

978 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

Browse Burkitt Lymphoma studies →

Open to participants now

58 of the 102 studies in Burkitt Lymphoma with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 132 Burkitt Lymphoma studies recruiting now, 41 (31%) set no upper age limit and 78 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Burkitt Lymphoma with a site in China, or all of them as a file.
02

Study summary

This is a multi-center Phase 2 study to determine the safety and efficacy of sepantronium bromide (SepB) in adult patients with relapsed or refractory high-grade B-cell lymphoma

Read the detailed description

This is a multi-center, open label, dose-ranging Phase 2 study evaluating the safety and efficacy of SepB in patients with relapsed/refractory c-Myc rearranged HGBCL.

Cohorts of three patients will be enrolled at each dose level for SepB with expansion to six patients, if necessary, to assess toxicity.

Following the completion of 2 cycles of treatment of each cohort, an independent Data Monitoring Committee (DMC) will review the safety data to assess study drug related toxicities from the current cohort. Following this review, a decision will be made to continue dose escalation to the next dose level, to declare that a given dose level is the level of dose-limiting toxicity (DLT) or to further explore toxicity at the dose level in question by enrolling additional subjects to a maximum of six subjects at that level.

An additional 6 patients will be enrolled at the recommended Phase 2 dose (RP2D). The RP2D will be established on the basis of the maximally tolerated dose between the two specified dose levels as well as other relevant data, including clinical signals of activity, pharmacokinetic (PK) and pharmacodynamic (PD) data.

03

Conditions studied

  • High-grade B-cell Lymphoma
  • Burkitt Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphatic Diseases
  • Lymphoma, High-Grade
  • C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
  • C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma
  • C-Myc Gene Rearrangement

Keywords

  • Relapsed/refractory
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed histologic diagnosis of c-Myc rearranged high-grade B-cell lymphoma
  • Relapse or disease after at least one
  • as defined by 2014 Lugano classification
  • performance status of 0-2
  • Acceptable coagulation parameters

Exclusion criteria

Exclusion Criteria:

  • transplant within 3 months
  • Autologous transplant without resolution of post-transplant cytopenias
  • Known CNS involvement
  • Average /QTc interval duration > 450 msec
  • Inadequate marrow, hepatic or renal function
  • Unresolved Grade 2 or greater toxicities from prior anticancer therapy
  • Radiotherapy within prior 4 weeks
  • Requires systemic therapy
  • Positive for Hepatis B or Hepatis C
  • Seropositive for
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Cohort 1 will receive a dose of 3.6 mg/m2/day of sepantronium bromide

    Drug: Sepantronium Bromide

  • Experimental
    Cohort 2

    Cohort 1 will receive a dose of 4.8 mg/m2/day of sepantronium bromide

    Drug: Sepantronium Bromide

  • Experimental
    Recommended Phase 2 Dose - Cohort 3

    The recommended Phase 2 dose will be established based on the safety, pharmacokinetic and pharmacodynamic data from Cohort 1 and Cohort 2

    Drug: Sepantronium Bromide

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and tolerability and recommended Phase 2 dose of sepantronium bromide

    Frequency, severity and relatedness of adverse events and the frequency of adverse events requiring discontinuation of study drug or dose reductions

    Time frame: From time of signing informed consent through 30 days after the last dose of study drug, an average of 6 months

Secondary outcomes

  1. Overall response rate

    The ORR is defined as the percentage of participants who achieve either a Partial Response or Complete Response at any time during the treatment phase

    Time frame: From first dose through the last dose of study drug, an average of 6 months

  2. Complete response rate

    Percentage of patients who experience a confirmed Complete Response at any time during the treatment phase

    Time frame: From first dose of study drug through the last dose of study drug, an average of 6 months

  3. Duration of response

    Time from the first documentation of a Complete Response or a Partial Response until the time to objective tumor progression

    Time frame: From first dose of study drug through to time of progression, an average of 6 months

  4. Clinical benefit rate

    Proportion of patients who achieve a Complete Response, Partial Response or Stable Disease during the treatment phase

    Time frame: From first dose of study drug through the last dose of study drug, an average of 6 months

  5. Overall survival

    The time from the first dose of study drug until death from any cause or date of last follow-up for living and lost to follow-up patients

    Time frame: From first dose of study drug through date of death, irrespective of cause, an average of 6 months

  6. Progression Free Survival

    The time from first dose until relapse, disease progression or death due to any cause

    Time frame: From first dose of study drug through relapse, disease progression or death due to any cause, an average of 12 months

07

Study locations

11 sites
  • Beijing Cancer Hospital
    Beijing, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, China
  • Henan Cancer Hospital
    Henan, China
  • Shanghai East Hospital
    Pudong, China
  • Tianjin Cancer Hospital
    Tianjin, China
  • Tongji Hospital
    Wuhan, China
  • Dong-A University Hospital
    Busan, South Korea
  • Inje University Haeundae Paik hospital
    Busan, South Korea
  • Samsung Medical Center
    Seoul, South Korea
  • Seoul National University Hospital
    Seoul, South Korea
  • Seoul St.Mary's Hospital
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)

Supporting information: Study protocol

Time frame: Beginning 9 months and ending 36 months following article publication.

Access criteria: Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Feb 2025, 26 months.

Of 92 phase 2 interventional studies under Burkitt Lymphoma, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 119. This study's 26 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Mar 2025 → Feb 2025 and completion Jun 2025 → Feb 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2022
First posted
Mar 2, 2022
StartActual
Dec 3, 2022
Primary completionActual
Feb 12, 2025was Mar 2025
CompletionActual
Feb 12, 2025was Jun 2025
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 4, 2026
Start date
Dec 9, 2022→Dec 3, 2022
Nov 4, 2026
Primary completion
Mar 1, 2025→Feb 12, 2025 (actual)
Nov 4, 2026
Study completion
Jun 30, 2025→Feb 12, 2025 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Active, not recruiting→Completed
    Start date Dec 9, 2022→Dec 3, 2022
    Primary completion Mar 1, 2025→Feb 12, 2025 (now actual)
    Study completion Jun 30, 2025→Feb 12, 2025 (now actual)
    + 3 other changes: index terms, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05263583
Lead sponsor
Cothera Bioscience, Inc
Responsible party
Sponsor
First posted
Mar 2, 2022
Start date
Dec 3, 2022
Primary completion
Feb 12, 2025
Completion
Feb 12, 2025
Last update
Nov 4, 2026

Study contacts

Vernon Jiang, PhD
study director · Cothera Bioscience

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sepantronium

Start the discussion